Health care--associated infections (HAIs) pose a potentially fatal threat to patients worldwide \[[@CIT0001]\], and *Staphylococcus aureus* is one of the most common causes of HAIs in the United States \[[@CIT0002], [@CIT0003]\]. Methicillin-resistant *S. aureus* (MRSA) bloodstream infections (BSIs) are linked with mortality of up to 30% and are associated with longer hospital stays and increased health care costs \[[@CIT0004], [@CIT0005]\]. MRSA has long been present in health care settings but is now well established in the community \[[@CIT0006]\]. The two dominant MRSA clones in the United States are clonal complex (CC) 5 and CC8 \[[@CIT0003]\]. Historically, CC5 has been associated with older individuals with hospital or long-term care facility contact \[[@CIT0006]\]. In contrast, CC8, predominantly the USA300 pulsotype, was first reported in the United States in healthy children in 1990s and raised concern for its capacity to cause severe disease in healthy individuals \[[@CIT0007]\]. Over the following two decades, CC8, largely driven by the USA300 lineage, became established as the predominant community-associated clone, presenting as skin and soft tissue infections (SSTIs) in athletes, children in day care centers, injection drug users, and persons with HIV infection \[[@CIT0008], [@CIT0009]\].

The prevalence of CC8 has increased in health care settings and is now associated with as many inpatient infections as CC5 \[[@CIT0006], [@CIT0009]\]. In this connection, we sought to update and expand on the clinical aspects of the molecular epidemiology of MRSA BSIs in a major academic medical center in New York City. We examined the differences between the two dominant clonal complexes, CC5 and CC8, and their associated clinical and epidemiological features. We additionally studied clonal associations in the context of current surveillance definitions, as defined by the National Healthcare Safety Network (NHSN), which are reportable \[[@CIT0010]\]. We explored clones in the context of associations with inpatient and outpatient community health care networks. Finally, we examined subgroups within the two CCs with an interest in the clinical features of the USA500, a relatively understudied clone \[[@CIT0011], [@CIT0012]\]. With extensive clinical detail, we describe a picture more complex than genotypic associations are able to describe.

METHODS {#s1}
=======

Study Setting, Patient Identification, and Molecular Typing {#s2}
-----------------------------------------------------------

The Mount Sinai Hospital (MSH) is a 1018-bed tertiary and quaternary care facility. Under the approval of the MSH institutional review board, data were captured on a total of 249 adult (≥18 years old) patients with MRSA BSIs identified by the MSH Clinical Microbiology Laboratory as part of standard clinical care between August 2014 and April 2017. Identification and susceptibility of MRSA was performed using VITEK®2 (bioMerieux). From a hospital-wide genomic surveillance program, we derived the CC and multilocus sequence typing (MLST) *in silico* using the RESTful interface to the *S. aureus* PubMLST \[[@CIT0013]\] database. Staphylococcal protein A (*spa*) and Panton-Valentine Leukocidin (PVL) were generated using a custom script (<https://github.com/mjsull/spa_typing>) and BLAST+ \[[@CIT0014]\], respectively. Core genome MLST types were determined using the schema available at <https://www.cgmlst.org/ncs/schema/141106/>. A tree for the visualization of clusters was created using GrapeTree \[[@CIT0015]\], using representative published NCBI references (USA500: CP007499.1; USA100: GCA_000525105; USA300: NC_007793.1). The raw sequence data have been deposited in the National Center for Biotechnology Information SRA database under Bioproject PRJNA470993.

Patient Data Collection {#s3}
-----------------------

Demographic and clinical data were obtained retrospectively from the electronic medical record system, including geographic admission data, presumed source of the BSI based on Infectious Diseases (ID) consult, comorbidities, and prior outpatient health care exposures. All patients diagnosed with MRSA BSI received a consultation from an ID specialist at the time of diagnosis, as per standard practice at our institution. The online database REDCap \[[@CIT0016]\] was used for data capture and to calculate the Charlson Comorbidity Index (CCI) \[[@CIT0017]\]. Patients with non-CC5 or CC8 MRSA were excluded, resulting in a total of 227 patients for analysis. ZIP codes were used to create a map of clones using the geographic information system (GIS) software ESRI Spatial Analysis \[[@CIT0018]\]. Surveillance definitions included hospital-onset MRSA (HO-MRSA), defined as positive cultures on or after the fourth day after hospital admission, and community-onset MRSA (CO-MRSA), defined as BSI presenting within the 72-hour hospital admission interval \[[@CIT0010]\].

Statistical Analysis {#s4}
--------------------

We selected established clinical correlates related to prior epidemiological studies, including demographics, baseline comorbidities, admission sources, and infection sources. We also evaluated in-hospital outcomes and death, especially those related to the MRSA BSI. Variables were collapsed to make the final set of covariates informative and reflective of current published literature. Analyses were performed in SAS (version 9.4) \[[@CIT0019]\], and all figures were produced using R (version 3.4.2) \[[@CIT0020]\]. Non--normally distributed continuous variables were categorized into discrete categorical groups. Variables were first analyzed in a univariate logistic regression model, with variables with *P* values ≤ .2 then placed into a multivariate logistic regression model. Mortality data were analyzed using a Cox regression model. All variables with *P* ≤ .05 were considered statistically significant.

RESULTS {#s5}
=======

Molecular Composition of Clones Involved in MRSA BSI {#s6}
----------------------------------------------------

Molecular analysis of single-patient, first-episode MRSA BSI revealed that the majority of MRSA BSIs were caused by the two dominant clones, CC5 and CC8 ([Figure 1](#F1){ref-type="fig"}; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). CC8 was the cause of BSI in 110 (44%), and CC5 was the cause of BSI in 117 (47%) of the total of 249 cases, representing 91% of the entire population. Only 22 (9%) were non-CC5/CC8. Within CC5, the majority were either sequence type (ST) 5 (n = 49; 42%) or ST105 (n = 61; 52%). Six percent (n = 7) belonged to other STs within CC5. The majority of CC8 isolates were ST8 (n = 108; 98%), with 2 (2%) additional non-ST8 clones. The majority (n = 64; 58%) of ST8 were *spa* type t008, along with 20 (18%) non-t008 *spa* types which also clustered with USA300. Additionally, CC8 included 24 (22%) *spa* type t064, including 3 (3%) non-t064 *spa* types, all clustering in the USA500 lineage \[[@CIT0011], [@CIT0021]\].

![Core genome multilocus sequence typing (cgMLST) of methicillin-resistant *Staphylococcus aureus* bloodstream infection isolates under study. Clustering of isolates into clonal complex (CC) 5 and CC8, as well as USA300 and USA500, was based on cgMLST data. Ridom *spa* types are listed on the right. The arrows point to the published NCBI reference genomes for each grouping. "Unknown" refers to a *spa* type not listed in the Ridom database.](ofz302f0001){#F1}

Baseline Clinical Characteristics of Patients With MRSA BSIs {#s7}
------------------------------------------------------------

Sixty-seven percent of patients were male, and the median age at diagnosis was 62 years ([Table 1](#T1){ref-type="table"}). The racial and ethnic composition included non-Hispanic white (n = 98; 43%), non-Hispanic black (n = 63; 28%), Hispanic/Latino (n = 46; 20%), Asian (n = 8; 4%), and not reported (n = 12; 5%). MRSA BSIs were linked to a wide range of causes, with vascular access (n = 78; 34%), pneumonia (n = 24; 11%), and SSTIs (n = 25; 11%) representing the most common causes.

###### 

Demographics and Clinical Characteristics of Patients With MRSA BSIs

  Factor, No. (%)                        MRSA BSI (n = 227)
  -------------------------------------- --------------------
   CC8                                   110 (48)
   CC5                                   117 (52)
  Sex                                    
   Male                                  151 (67)
   Female                                76 (33)
  Race/ethnicity                         
   Non-Hispanic white                    98 (43)
   Non-Hispanic black                    63 (28)
   Hispanic/Latino                       46 (20)
   Asian                                 8 (4)
   Unknown                               12 (5)
  Age at time of infection               
   18--54 y                              79 (35)
   55--69 y                              68 (30)
   ≥70 y                                 80 (35)
  History of injection drug use          24 (11)
  HIV                                    22 (10)
  Admission source                       
    ^a^Home                              132 (58)
   NH/rehab/LTACH                        60 (26)
   Outside hospital                      35 (15)
  Prior hospital admission (90 d)        162 (71)
  Length of hospital stay prior to BSI   
   ≤3 d                                  132 (58)
   \>3 d                                 95 (42)
  Frequent health care interaction       
   Hemodialysis                          40 (18)
    ^b^Infusion center                   34 (15)
   None                                  153 (67)
  ^c^Presence of invasive device         180 (79)
  ^d^Invasive procedures                 109 (48)
  ^e^Wound present                       94 (41)
  ^f^Comorbidities                       
   Myocardial infarction                 24 (11)
   Congestive heart failure              55 (24)
   Peripheral vascular disease           37 (16)
   Cerebrovascular disease               20 (9)
   Dementia                              29 (13)
   Chronic pulmonary disease             30 (13)
   Connective tissue disease             5 (2)
   Peptic ulcer disease                  9 (4)
   Mild liver disease                    2 (1)
   Diabetes (no complications)           38 (17)
   Diabetes with organ damage            51 (22)
   Para- or hemiplegia                   17 (7)
   Moderate/severe renal disease         55 (24)
   Solid tumor                           23 (10)
   Leukemia                              13 (6)
   Lymphoma/multiple myeloma             26 (11)
   Moderate/severe liver disease         17 (7)
   Metastatic solid tumor                14 (6)
  Charlson Comorbidity Index             
   0--3                                  71 (31)
   4--5                                  48 (21)
   6--8                                  66 (29)
   \>8                                   42 (19)
  ^g^History of transplant               32 (14)
  ^h^History of MRSA colonization        94 (41)
  Presumed source of MRSA BSI            
   Peripheral intravenous catheter       16 (7)
   Skin & soft tissue infection          25 (11)
   Pneumonia                             24 (11)
   Diabetic foot infection               17 (7)
   Vascular access                       78 (34)
   Septic arthritis                      4 (2)
   Urinary source                        4 (2)
   Sacral wound                          11 (5)
   Other/unknown                         28 (12)
  ICU admission prior to BSI             42 (19)

Abbreviations: BSI, blood stream infection; CC, clonal complex; ICU, intensive care unit; LTACH, long-term acute care hospital; MRSA, methicillin-resistant *Staphylococcus aureus*.

^a^"Admission from home": included nonmedical residences such as home, group homes, assisted living facilities, and homeless shelters.

^b^"Infusion center": outpatient centers for chemotherapy, intravenous fluids, intravenous immunomodulators, and blood products.

^c^"Presence of invasive device": included pacemaker, implantable cardioverter defibrillator (ICD), left ventricular assist device (LVAD), vascular access (excluding peripheral intravenous catheters), orthopedic hardware, nephrostomy, suprapubic catheter, ileal conduit, foley catheter, arteriovenous graft placement (AVG), percutaneous endoscopic gastrostomy (PEG) tube, or ostomy.

^d^"Invasive procedures": included any invasive procedures or surgery occurring within 1 month before first positive blood culture for MRSA, excluding electroencephalogram (EEG), electrocardiogram (EKG), and transthoracic echocardiogram (TTE).

^e^"Wound present": presence of a chronic skin wound overlying the sacrum, limb, abdomen, or other body part.

^f^"Comorbidities": as defined by the Charleston Comorbidity Index (CCI); refer to standard definitions for CCI \[[@CIT0017]\].

^g^"History of transplant": included solid organ and bone marrow transplant.

^h^"History of MRSA colonization": any positive culture from urine, sputum, tissue, or nares with MRSA prior to the positive MRSA blood culture or a documented history of prior MRSA infection or colonization.

We performed a comprehensive analysis of admission sources. More than half of patients were admitted from home (n = 128; 56%), with the remaining patients transferred in from nursing homes/rehabilitation/long-term care facilities (n = 60; 26%), outside hospitals (n = 35; 15%), or homeless shelters (n = 4; 2%) ([Table 1](#T1){ref-type="table"}). Of subjects residing at home or in group home settings, 32% (n = 56) had frequent contact with health care centers either via outpatient dialysis (n = 22; 12%) or infusion centers (n = 34; 19%). Only 27 (12%) study patients had no significant inpatient or outpatient health care exposure.

The mean CCI of subjects on hospital admission was 5.4. The most common comorbid medical conditions in our data set were congestive heart failure (n = 55; 24%) and chronic renal disease (n = 55; 24%). Ten percent (n = 22) of patients were coinfected with HIV. Additionally, 32 (14%) had a history of a transplant (solid organ or bone marrow). Injection drug use was reported by 11% (n = 24) of our population, and 41% (n = 94) had a history of MRSA colonization.

Clinical Features and Geographic Distribution of the two Dominant MRSA Clones {#s8}
-----------------------------------------------------------------------------

As CC5 and CC8 were responsible for the majority of BSIs, we anchored our analyses on comparing these two clones. The majority of variables examined were not significantly increased in one clone over the other, with several notable exceptions. Race was found to confound the effects of HIV and injection drug use, so these two variables were retained in the final model. Logistic regression revealed that those of non-Hispanic black race (odds ratio \[OR\], 3.45; 95% confidence interval \[CI\], 1.51--7.87; *P* = .003), of Hispanic/Latino race (OR, 3.21; 95% CI, 1.33--7.77; *P* = .01), with HIV (OR, 3.62; 95% CI, 1.01--12.92; *P* = .05), and with SSTIs (OR, 2.21; 95% CI, 0.98--10.46; *P* = .05) had a higher likelihood of being infected with CC8 ([Table 2](#T2){ref-type="table"}). Interestingly, CC8 was also increased in patients with peripheral intravenous catheters (PIVs) as the presumed source of MRSA BSI compared with CC5 (OR, 5.96; 95% CI, 1.51--23.50; *P* = .01). Alternately, patients were less likely to have BSI with CC8 if they were aged \>70 years (OR, 0.28; 95% CI, 0.11--0.74; *P* = .01) or if they were admitted from an outside hospital (OR, 0.33; 95% CI, 0.11--1.00; *P* = .05) vs home.

###### 

Demographics and Clinical Characteristics of Patients With MRSA BSIs Stratified by Clonal Complex With the Odds of Being CC8 vs CC5

  Factor                                 CC8       CC5        Univariate Analysis                   Multivariate Analysis    
  -------------------------------------- --------- ---------- ------------------------ ------------ ------------------------ ----------
  Male                                   73 (66)   78 (67)    0.99 (0.57--1.71)        .96                                   
  Race/ethnicity                                                                                                             
   Non-Hispanic white                    31 (28)   67 (57)    Reference                             Reference                
   Non-Hispanic black                    41 (37)   22 (19)    **4.03 (2.06--7.87)**    **\<.001**   **3.45 (1.51--7.87)**    **.003**
   Hispanic/Latino                       27 (25)   19 (16)    **3.07 (1.49--6.34)**    **.002**     **3.21 (1.33--7.77)**    **.01**
   Asian                                 4 (4)     4 (3)      2.16 (0.51--9.21)        .30          3.17 (0.61--16.38)       .17
   Unknown                               7 (6)     5 (4)      3.03 (0.89--10.29)       .08          2.14 (0.50--9.13)        .30
  Age at time of infection                                                                                                   
   18--54 y                              50 (45)   29 (25)    Reference                             Reference                
   55--69 y                              37 (34)   31 (27)    0.69 (0.36--1.34)        .28          0.64 (0.27--1.50)        .30
   ≥70 y                                 23 (21)   57 (49)    **0.23 (0.12--0.46)**    **\<.001**   **0.28 (0.11--0.74)**    **.01**
  History of injection drug use          16 (15)   8 (6)      2.32 (0.95--5.66)        .06          0.62 (0.21--1.88)        .40
  HIV                                    18 (16)   4 (3)      **5.53 (1.81--16.90)**   **.003**     **3.62 (1.01--12.92)**   **.05**
  Admission source                                                                                                           
    Home                                 78 (71)   54 (46)    Reference                             Reference                
    NH/rehab/LTACH                       23 (21)   37 (32)    **0.43 (0.23--0.80)**    **.008**     0.55 (0.24--1.26)        .16
    Other hospital                       9 (8)     26 (22)    **0.24 (0.10--0.55)**    **\<.001**   **0.33 (0.11--1.00)**    **.05**
  Prior hospital admission (90 d)        70 (64)   92 (79)    **0.48 (0.26--0.86)**    **.01**      1.00 (0.43--2.32)        .99
  Length of hospital stay prior to BSI                                                                                       
   ≤3 d                                  74 (67)   58 (50)    **2.09 (1.22--3.58)**    **.007**     2.01 (0.90--4.50)        .09
   \>3 d                                 36 (33)   59 (50)    Reference                             Reference                
  Frequent health care interaction                                                                                           
   Hemodialysis                          22 (20)   18 (15)    1.45 (0.72--2.92)        .30                                   
   Infusion center                       18 (16)   16 (14)    1.33 (0.63--2.81)        .45                                   
   None                                  70 (64)   83 (71)    Reference                                                      
  Presence of invasive device            77 (70)   103 (88)   **0.32 (0.16--0.63)**    **.001**     0.56 (0.24--1.32)        .18
  Invasive procedures                    44 (40)   65 (56)    **0.53 (0.32--0.90)**    **.02**      0.67 (0.30--1.48)        .32
  Wound present                          46 (42)   48 (41)    1.03 (0.61--1.75)        .90                                   
  Charlson Comorbidity Index                                                                                                 
   0--3                                  40 (36)   31 (27)    Reference                             Reference                
   4--5                                  26 (24)   22 (19)    0.92 (0.44--1.91)        .82          1.34 (0.50--3.57)        .56
   6--8                                  30 (27)   36 (31)    0.65 (0.33--1.27)        .20          1.09 (0.42--2.85)        .85
   \>8                                   14 (13)   28 (24)    **0.39 (0.18--0.86)**    **.02**      0.74 (0.22--2.49)        .63
  History of transplant                  14 (13)   18 (15)    0.80 (0.38--1.70)        .57                                   
  History of MRSA colonization           47 (43)   47 (40)    1.11 (0.66--1.89)        .70                                   
  Presumed source of MRSA BSI                                                                                                
   Peripheral intravenous catheter       11 (10)   5 (4)      2.49 (0.84--7.41)        .10          **5.96 (1.51--23.50)**   **.01**
   Skin & soft tissue infection          18 (16)   7 (6)      **3.08 (1.23--7.68)**    **.02**      **2.21 (0.98--10.46)**   **.05**
   Pneumonia                             12 (11)   12 (10)    1.07 (0.46--2.50)        .87                                   
   Diabetic foot infection               8 (7)     9 (8)      0.94 (0.35--2.53)        .90                                   
   Vascular access                       35 (32)   43 (37)    0.80 (0.46--1.39)        .43                                   
   Septic arthritis                      1 (1)     3 (3)      0.35 (0.04--3.40)        .36                                   
   Urinary source                        1 (1)     3 (3)      0.35 (0.04--3.40)        .36                                   
   Sacral wound                          6 (5)     5 (4)      1.29 (0.38--4.36)        .68                                   
   Other/unknown                         12 (11)   16 (14)    0.77 (0.35--1.72)        .53                                   
  ICU admission prior to BSI             16 (15)   26 (22)    0.60 (0.30--1.18)        .14          1.47 (0.53--4.07)        .46

See [Table 1](#T1){ref-type="table"} for definitions. Bold indicates significance at ≤.05.

Abbreviations: BSI, bloodstream infection; ICU, intensive care unit; LTACH, long-term acute care hospital; NH, nursing home; rehab, rehabilitation facility.

On multivariate analysis, there were equal proportions of CC8 vs CC5 across patient admission sources. We further mapped the clones according to patient ZIP code and found no significant clustering aside from the area surrounding the hospital ([Supplementary Figure 1](#sup2){ref-type="supplementary-material"}).

Clinical Characteristics of Patients With MRSA BSI due to Clonal Subgroups {#s9}
--------------------------------------------------------------------------

Although we performed our top-level analysis at the CC level, we additionally evaluated potential clinical differences between subgroups within the CCs. In CC8, a total of 27 CC8 isolates clustered with USA500, which is considered a health care--associated clone \[[@CIT0011], [@CIT0012], [@CIT0021]\]. We thus compared USA500 with USA300 and found few overall differences, aside from a higher proportion of USA500 in those with HIV (OR, 6.61; 95% CI, 1.38--31.67; *P* = .02) ([Supplementary Table 2](#sup2){ref-type="supplementary-material"}). We also compared ST105 and ST5 lineages within CC5, which had few clinical distinctions ([Supplementary Table 3](#sup2){ref-type="supplementary-material"}). Stepwise removal of any of these subgroups did not impact the results of our top-level CC8 vs CC5 analyses; thus they were retained in the analyses.

Addressing Surveillance Definitions in Endemic Settings {#s10}
-------------------------------------------------------

Given the importance placed on reporting BSIs based on NHSN definitions, we sought to provide clinical detail to the BSIs in the context of these definitions \[[@CIT0010]\]. Overall, there were more CO-MRSA BSIs (n = 132; 58%) than HO-MRSA BSIs (n = 95; 42%). Logistic regression revealed that patients characterized as CO-MRSA were more likely to have CC8 (OR, 2.33; 95% CI, 1.03--5.27; *P* = .04) and more likely to be receiving hemodialysis at the time of infection (OR, 4.62; 95% CI, 1.23--17.29; *P* = .02) ([Table 3](#T3){ref-type="table"}). Conversely, CO-MRSA was less likely to be associated with prior invasive procedures (OR, 0.18; 95% CI, 0.08--0.40; *P* ≤ .001), MRSA BSI from a PIV (OR, 0.11; 95% CI, 0.03--0.46; *P* = .002), MRSA BSI from vascular access (OR, 0.36; 95% CI, 0.13--0.95; *P* = .04), and intensive care unit (ICU) admission prior to BSI (OR, 0.13; 95% CI, 0.04--0.43; *P* ≤ .001). Only 27 (12%) patients had no clear health care exposure; thus 88% of our total patient population had health care risk factors prior to their MRSA BSI.

###### 

Demographics and Clinical Characteristics of Patients With MRSA BSIs Stratified by NHSN Definitions With the Odds of Having CO-MRSA vs HO-MRSA

  Factor                              CO-MRSA   HO-MRSA   Univariate Analysis                   Multivariate Analysis    
  ----------------------------------- --------- --------- ------------------------ ------------ ------------------------ ------------
  CC8                                 74 (56)   36 (38)   **2.09 (1.22--3.58)**    **.007**     **2.33 (1.03--5.27)**    **.04**
  Male                                90 (68)   61 (64)   1.19 (0.68--2.08)        .53                                   
  Race/ethnicity                                                                                                         
   Non-Hispanic white                 50 (38)   48 (51)   Reference                             Reference                
   Non-Hispanic black                 40 (30)   23 (24)   1.67 (0.87--3.19)        .12          1.14 (0.44--3.00)        .79
   Hispanic/Latino                    30 (23)   16 (17)   1.80 (0.87--3.72)        .11          1.12 (0.36--3.43)        .85
   Asian                              6 (5)     2 (2)     2.88 (0.55--14.98)       .21          2.67 (0.36--19.62)       .33
   Unknown                            6 (5)     6 (6)     0.96 (0.29--3.18)        .95          1.08 (0.21--5.47)        .93
  Age at time of infection                                                                                               
   18--54 y                           43 (33)   36 (38)   Reference                                                      
   55--69 y                           44 (33)   24 (25)   1.54 (0.79--2.99)        .21                                   
   ≥70 y                              45 (34)   35 (37)   1.08 (0.58--2.01)        .82                                   
  History of injection drug use       18 (14)   6 (6)     2.34 (0.89--6.15)        .08          0.56 (0.15--2.14)        .40
  HIV                                 13 (10)   9 (9)     1.04 (0.43--2.55)        .93                                   
  Admission source                                                                                                       
    Home                              80 (61)   52 (55)   Reference                             Reference                
    NH/rehab/LTACH                    40 (30)   20 (21)   1.30 (0.69--2.47)        .42          0.89 (0.34--2.30)        .81
    Other hospital                    12 (9)    23 (24)   **0.34 (0.16--0.74)**    **.007**     0.78 (0.25--2.46)        .67
  Prior hospital admission (90 d)     91 (69)   71 (75)   0.75 (0.42--1.36)        .34                                   
  Frequent health care interaction                                                                                       
   Hemodialysis                       33 (25)   7 (7)     **3.48 (1.45--8.36)**    **.005**     **4.62 (1.23--17.29)**   **.02**
   Infusion center                    11 (8)    23 (24)   **0.35 (0.16--0.78)**    **.01**      0.35 (0.12--1.07)        .07
   None                               88 (67)   65 (68)   Reference                             Reference                
  Presence of invasive device         95 (72)   85 (89)   **0.30 (0.14--0.64)**    **.002**     0.54 (0.19--1.55)        .25
  Invasive procedures                 37 (28)   72 (76)   **0.12 (0.07--0.23)**    **\<.001**   **0.18 (0.08--0.40)**    **\<.001**
  Wound present                       58 (44)   36 (38)   1.29 (0.75--2.20)        .36                                   
  Charlson Comorbidity Index                                                                                             
   0--3                               38 (29)   33 (35)   Reference                             Reference                
   4--5                               24 (18)   24 (25)   0.87 (0.42--1.81)        .71          1.48 (0.51--4.23)        .47
   6--8                               40 (30)   26 (27)   1.34 (0.68--2.64)        .40          1.08 (0.40--2.92)        .88
   \>8                                30 (23)   12 (13)   2.17 (0.96--4.91)        .06          2.13 (0.62--7.25)        .23
  History of transplant               13 (10)   19 (20)   **0.44 (0.20--0.94)**    **.03**      1.11 (0.38--3.23)        .85
  History of MRSA colonization        58 (44)   36 (38)   1.29 (0.75--2.20)        .36                                   
  Presumed source of MRSA infection                                                                                      
   Peripheral intravenous catheter    6 (5)     10 (11)   0.41 (0.14--1.16)        .09          **0.11 (0.03--0.46)**    **.002**
   Skin & soft tissue infection       17 (13)   8 (8)     1.61 (0.66--3.90)        .29                                   
   Pneumonia                          14 (11)   10 (11)   1.01 (0.43--2.38)        .98                                   
   Diabetic foot infection            15 (11)   2 (2)     **5.96 (1.33--26.73)**   **.02**      2.04 (0.33--12.45)       .44
   Vascular access                    36 (27)   42 (44)   **0.47 (0.27--0.83)**    **.009**     **0.36 (0.13--0.95)**    **.04**
   Septic arthritis                   2 (2)     2 (2)     0.72 (0.10--5.17)        .74                                   
   Urinary source                     3 (2)     1 (1)     2.18 (0.22--21.30)       .50                                   
   Sacral wound                       9 (7)     2 (2)     3.40 (0.72--16.12)       .12          0.70 (0.11--4.55)        .71
   Other/unknown                      16 (12)   12 (13)   0.95 (0.43--2.12)        .91                                   
  ICU admission prior to BSI          5 (4)     37 (39)   **0.06 (0.02--0.17)**    **\<.001**   **0.13 (0.04--0.43)**    **\<.001**

See [Table 1](#T1){ref-type="table"} for definitions. Bold indicates significance at ≤.05.

Abbreviations: BSI, bloodstream infection; ICU, intensive care unit; LTACH, long-term acute care hospital; NH, nursing home; NHSN, National Healthcare Safety Network; rehab, rehabilitation facility.

We also examined CC8 vs CC5 in the context of the NHSN definitions. CC8 was responsible for 38% of HO-MRSA BSIs and was associated with younger age and non-Hispanic black race ([Supplementary Tables 4 and 5](#sup2){ref-type="supplementary-material"}). Among patients grouped into the HO-MRSA stratum, those whose MRSA BSI resulted from a PIV (OR, 9.84; 95% CI, 1.46--66.50; *P* = .02) were more likely to be from CC8. We also explored clones and definitions in the context of the individual comorbidities that constitute the CCI, and we found that those with lymphoma and/or multiple myeloma (OR, 0.30; 95% CI, 0.11--0.80; *P* = .02) were more likely to occur among HO-MRSA, yet in the CO-MRSA stratum, lymphoma and/or multiple myeloma was more likely to involve CC5 (OR, 0.05; 95% CI, 0.01--0.48; *P* = .01).

Differences in Morbidity and Mortality Related to MRSA BSIs {#s11}
-----------------------------------------------------------

Morbidity outcomes associated with MRSA BSI such as the need for ICU admission, need for mechanical ventilation, and development of metastatic complications were studied with respect to clone. Overall, we found no differences in morbidity between the two clones ([Supplementary Table 6C, D](#sup2){ref-type="supplementary-material"}). Interestingly, strictly CO-MRSA had overall worse hospital outcomes, with increased ICU admissions (OR, 10.73; 95% CI, 3.94--29.26; *P* ≤ .001), mechanical ventilation (OR, 3.45; 95% CI, 1.30--9.15; *P* = .01), and metastatic complications (OR, 3.34; 95% CI, 1.46--7.64; *P* = .004) associated with MRSA BSI ([Supplementary Table 6B](#sup2){ref-type="supplementary-material"}). Overall, 20% (n = 46) had persistent bacteremia (defined as BSI lasting \>7 days), with no clonal predominance in these cases.

With regard to mortality, we examined 90-day all-cause and 90-day mortality associated with MRSA BSI. All-cause 90-day mortality was 27% (n = 61), and of those who died at 90 days, death was associated with MRSA BSI in 54% (n = 33) of cases. All-cause 90-day mortality had a lower likelihood of death due to CC8 vs CC5 (OR, 0.55; 95% CI, 0.30--1.00; *P* = .05), which was also observed in the CO-MRSA stratum (OR, 0.43; 95% CI, 0.19--0.99; *P* = .05).

As a correlate for pathogenesis, we examined whether one clone had higher 90-day mortality in the setting of MRSA BSI. We first looked solely at the survival curves of each clone ([Supplementary Figure 2](#sup2){ref-type="supplementary-material"}), which revealed no difference. Second, we examined the clone variable in a multivariate Cox regression with possible confounders ([Supplementary Figure 3](#sup2){ref-type="supplementary-material"}). Interestingly, there was no difference in MRSA-related 90-day mortality related to MRSA with respect to clones (OR, 0.91; 95% CI, 0.45--1.85; *P* = .79). Ninety-day mortality related to MRSA was more likely to occur in individuals aged \>70 years (OR, 4.48; 95% CI, 1.71--11.73; *P* = .002) and those with metastatic solid tumors (OR, 3.79; 95% CI, 1.25--11.51; *P* = .02). Finally, we examined 90-day mortality associated with MRSA BSI due to primary sources of bacteremia, which revealed higher mortality with MRSA BSI from pneumonia (OR, 2.93; 95% CI, 0.98--8.74; *P* = .05) or septic arthritis (OR, 5.80; 95% CI, 1.05--32.13; *P* = .04).

DISCUSSION {#s12}
==========

As clones causing invasive MRSA infections are tied to specific populations, syndromes, and settings and are thought to behave differently, we sought to unravel how these associations manifest clinically in BSIs in a high-level care institution in an endemic region. This study represents a large cohort of patients who were selected based strictly on presence of invasive disease (bacteremia) and demonstrated highly complex cases linked to significant morbidity and mortality. Consistent with previous reports from our region \[[@CIT0022], [@CIT0023]\] and across the United States \[[@CIT0003]\], the majority of isolates were either CC5 or CC8. We demonstrated that CC8, representing half of all MRSA BSIs, was more frequently seen in those of younger age and nonwhite race. These data support the described convergence of clinical features classically associated with the two dominant clones \[[@CIT0006], [@CIT0024]\]. Although stratification by surveillance definitions was consistent with clones to an extent, it questions the applicability of definitions in endemic regions. These findings provide support for the concept that classic community genotypes involve individuals with frequent health care interactions \[[@CIT0025]\].

Although CC8/USA300 has been considered hypervirulent, as it causes disease in younger, healthier individuals \[[@CIT0024], [@CIT0026], [@CIT0027]\], work performed in animal models does not always actualize in complex human infections \[[@CIT0028]\]. Our study did not find significant differences in mortality or other outcomes based on MRSA clone, even after adjusting for comorbidities. This suggests that apparent differences driving morbidity and mortality are not solely due to differences between genotypes but due to a complex combination of demographic, host, and genomic factors, which require further study in human populations. Patients in our study had a CCI of 5.4, which is higher than most other studies that cite CCIs between 1.5 and 3 \[[@CIT0017], [@CIT0024]\]. We found increased mortality in the setting of MRSA BSI among those older than 70 years and those with metastatic solid tumors. Although these underlying conditions are independently associated with an increased risk of death, these data suggest that these populations have worse outcomes over other comorbid conditions when they develop MRSA BSI, and are hence a focus in future interventions. Finally, a higher proportion of males had MRSA BSI in our study, consistent with prior studies \[[@CIT0029], [@CIT0030]\].

Of interest was the increase in BSIs due to USA500 in people with HIV (PWH), a finding echoed in recent abstracts \[[@CIT0031], [@CIT0032]\]. This increase in the incidence of HIV among those with USA500 suggests that the types of MRSA infecting PWH may be shifting away from the historical USA300 \[[@CIT0006]\]. As USA500 is considered a health care clone \[[@CIT0006], [@CIT0011], [@CIT0012]\], this may reflect the changing epidemiology and management of HIV as it becomes a more chronic condition.

We describe increased CC8 in PIV-related BSIs, which was also significant in the HO-MRSA stratum. Source determination was based on the documentation of thrombophlebitis in all cases, as described in detail by ID consultants. We did not label PIV as the source unless it was clearly stated by ID clinicians to be the actual source, and we ensured that these infections were not incorrectly categorized as other types of skin infections. PIV placement is an aseptic but not a sterile procedure, and more emphasis and attention are placed on maintenance of central venous catheters than on PIVs. Although the incidence of PIV-related BSIs is low, the high frequency of PIV use results in a significant portion of PIVs resulting in BSIs \[[@CIT0033]\]. BSIs derive from colonizing flora \[[@CIT0034]\], and the CC8 (USA300 in particular) is associated with skin colonization \[[@CIT0035]\], which is supported in our data by the increase in CC8 in the setting of SSTIs. For the PIV infections and CC8 association in the HO-MRSA stratum, the most likely explanation is that patients are already colonized with CC8 and subsequently become infected with their isolate after PIV-related complications \[[@CIT0036]\]. This work further builds upon community origins of HO-MRSA BSIs by adding the association of CC8 with PIVs among patients with HO-MRSA \[[@CIT0037]\]. A larger sample size and access to colonizing isolates would assist in expansion of this concept, highlight under-recognized HAIs \[[@CIT0029],[@CIT0038]\], and assist in evaluating the role of patient hygiene.

This study also examined the challenges of current surveillance definitions to describe these infections. A striking 88% of all patients had previous health care exposures, and 80% of the strictly CO-MRSA had prior health care exposures. An alternative definition of community-onset health care--associated (CO-HCA) BSIs that present within 3 days of hospital admission in patients with frequent health care exposure \[[@CIT0004], [@CIT0026]\] may be more appropriate to report. We also describe that those presenting with BSIs from the community are a medically complex group with poor outcomes, consistent with studies associating CO-MRSA with complicated bacteremia \[[@CIT0039]\]. Furthermore, those infected with the CO-MRSA with CC5 were well advanced in their disease course, either through delay of presentation to the hospital or through transfers from other facilities for advanced care (52 \[39%\] of admissions in the CO-MRSA group were admitted from other facilities). It appears that future descriptions of these classifications should include the changing epidemiology of the patients and their complex medical experiences.

This study has several limitations. As a retrospective study, it is subject to errors in chart abstraction. Being a single-institution study, findings from the medically complex population studied may not be generalizable to smaller community hospitals. Our primary end point of mortality may be subject to reporting bias, as death occurring outside the hospital may not have been captured in medical records. Although we recognize that methicillin-susceptible *S. aureus* (MSSA) also causes significant disease, we focused on MRSA-BSI due to the focus of our molecular surveillance program \[[@CIT0040]\]. Similar analyses extending beyond BSIs and including MSSA are critical.

In a highly complex patient population, there remain few distinct differences in the characteristics associated with the two endemic clones. CC8 has become even more common in the hospital, and it behaves similarly to CC5 by infecting infirm individuals. There were likewise no significant differences in both morbidity and mortality outcomes. Our study also highlights shifts in molecular epidemiology, at-risk populations, and potential areas for prevention such as PIVs in order to forestall this fatal disease. Integration of these clinical correlates with genomic and other multiscale analyses will lead to a more complete understanding of the pathogenesis of *S. aureus*.

Supplementary Data {#s13}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

***Financial support. ***This research was supported in part by the CTSA/NCATS KL2 Program (KL2TR001435, Icahn School of Medicine at Mount Sinai; D.R.A), the New York State Department of Health Empire Clinical Research Investigator Program (Awarded to Judith A. Aberg; Icahn School of Medicine at Mount Sinai; D.R.A.), and R01 AI119145 (H.v.B.).

***Disclaimer. ***The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.

***Potential conflicts of interest. ***All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
